Oral roxadustat three times weekly in ESA‐naïve and ESA‐converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies-Reference-Cited by-同舟云学术

Oral roxadustat three times weekly in ESA‐naïve and ESA‐converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies

Published:2020-02-05 Issue:6 Volume:24 Page:628-641
ISSN:1744-9979
Container-title:Therapeutic Apheresis and Dialysis
language:en
Short-container-title:Ther Apher Dial

Author:

Akizawa Tadao¹,Ueno Mai²,Shiga Takanori²,Reusch Michael³

Affiliation:

1. Showa University School of Medicine Tokyo Japan

2. Astellas Pharma, Inc. Tokyo Japan

3. Astellas Pharma Europe B.V. Leiden The Netherlands

Publisher

Wiley

Subject

Nephrology,Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1744-9987.13468

Reference16 articles.

1. Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients

2. An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney disease

3. KDIGO clinical practice guideline for anemia in chronic kidney disease;KDIGO;Kidney Int Suppl,2012

4. Statin therapy and erythropoiesis-stimulating agent hyporesponsiveness in patients with nondialysis chronic kidney disease

5. Burden of Anemia in Chronic Kidney Disease Patients in Japan: A Literature Review

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beyond the Surface: A Narrative Review Examining the Systemic Impacts of Recessive Dystrophic Epidermolysis Bullosa;Journal of Investigative Dermatology;2024-09

2. Evaluating the safety and efficacy of vadadustat for the treatment of anemia associated with chronic kidney disease;Expert Opinion on Pharmacotherapy;2024-06-12

3. Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Phase 3 Roxadustat Trials in Japan;Advances in Therapy;2024-02-16

4. Impact of C-reactive protein on the effect of Roxadustat for the treatment of anemia in chronic kidney disease: a systematic review of randomized controlled trials;BMC Nephrology;2024-02-05

5. A phase 3b, multicenter, open‐label, single‐arm study of roxadustat within a US dialysis organization: The DENALI study;Hemodialysis International;2023-10-24